Risk of suicide and psychiatric disorders among isotretinoin users: a meta-analysis

Analysis (25 studies; n=1,625,891) found no epidemiological evidence to suggest increased relative risk of suicide/psychiatric conditions at population level (1-year absolute risk of completed suicide, suicide attempt, suicide ideation, & self-harm <0.5% each, & depression 3.83%)

SPS commentary:

An editorial discusses the totality of the findings, together with previous evidence, noting this study has added usefully to the literature in this area, but the findings are far from the final word.

In April 2023, the Isotretinoin Expert Working Group of the Commission on Human Medicines made recommendations to strengthen the safety of isotretinoin treatment. They included new warnings, the need for consistent monitoring requirements for psychiatric side effects, the introduction of new monitoring requirements for sexual side effects, and additional oversight of the initiation of treatment for patients younger than 18 years. Prescribers of isotretinoin were reminded of the need to fully inform all patients of the potential benefits and risks associated with isotretinoin treatment and monitor patients closely for any side effects throughout treatment.

 

JAMA Dermatology

Resource links:

Editorial